Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan
K. Yoshimura, Kenro Hirata, Chiyo K. Imamura, Y. Yamamoto et al.
Citations
1 citations
Journal
EClinicalMedicine
Topics
Gastric Cancer Management and Outcomes
Field-Weighted Citation Impact (FWCI)
36.44
article
Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan
K. Yoshimura, Kenro Hirata, Chiyo K. Imamura, Y. Yamamoto, S. Hironaka, H. Kawakami, Michitaka Nagase, Chihiro Kondoh, Takeshi Kajiwara, Hisateru Yasui, Yasuo Hamamoto, Kentaro Yamazaki, Hiroo Katsuya, Takayuki Ando, Naotoshi Sugimoto, Hiroki Hara, Eishi Baba, Hirokazu Shoji, Kei Muro
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 92
Institutions
SHOWA Medical University (JP), Tokyo Medical and Dental University (JP), Kyushu University (JP), University of Tsukuba (JP), Saga University (JP), Kyorin University (JP), Tohoku University (JP), Keio University (JP), Shizuoka Cancer Center (JP), Nagoya University Hospital (JP), Osaka International Cancer Institute (JP), Saku Central Hospital (JP), Keio University Hospital (JP), University of Tsukuba Hospital (JP), Saitama Cancer Center (JP), Hiroshima University Hospital (JP), Aichi Cancer Center (JP), Shikoku Cancer Center (JP), Kobe City Medical Center General Hospital (JP), Toranomon Hospital (JP), University of Toyama (JP), Kindai University (JP)